ClinicalTrials.gg
Not yet recruitingNCT07944352AYSUpdated Nov 18, 2026

The Almond Yogurt Study (AYS)

An interventional study of Yogurt with almonds in This Study Explores the Relationships Between Almond Particle Size, Chewing, Gastric Emptying, and Postprandial Metabolism, sponsored by University of Guelph. Not yet recruiting at 1 site in Canada. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Guelph · Not applicable, Interventional, and Basic science

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to explore how almond food structure influences gastric emptying rates when consumed by healthy adult women as part of a standardized breakfast meal. The main questions it aims to answer are:

  • Does the structure of almonds (whole, chopped, buttered) influence gastric emptying ?
  • What is the correlation between chewing behaviour, gastric emptying, and changes in postprandial triacylglycerols and satiety (hormones and ratings) within the context of an increasingly disrupted nut matrix.
Read the detailed description

This study is investigating how the structure of almonds (whole, chopped, buttered) as part of a yogurt-based breakfast meal influences gastric emptying and postprandial metabolism. Over three randomized visits, fasted healthy adult female participants will arrive at the research centre where an iv-catheter will be inserted for serial blood sampling over 6 hours for analysis of plasma triacylglycerols, GLP-1, CCK, glucose, and insulin. Participants will consume each meal while being video recorded to quantify chewing frequency and eating time. Paper questionnaires will periodically assess participants' eating experiences and hunger sensations throughout the visit (e.g., exertion, liking, hunger, fullness). Gastric ultrasonography will be used to visualize and quantify the cross-sectional area of the gastric antrum so that changes in gastric volume can be tracked over time. Overall, this study aims to determine how almond form, as an example of food structure, influences chewing, gastric emptying, satiety and postprandial metabolism.

02

Conditions studied

  • This Study Explores the Relationships Between Almond Particle Size, Chewing, Gastric Emptying, and Postprandial Metabolism

Keywords

  • Almonds
  • Particle size
  • Satiety
  • Postprandial glycemia
  • Postprandial lipemia
  • Food matrix
  • Chewing exertion
  • Yogurt
  • Gastric emptying
03

In context

Lead sponsor

University of Guelph is the lead sponsor of 71 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female adults aged 18-45 years.
  • (BMI) between 18.5-27.9 kg/m2, or waist circumference of less than 88 cm
  • Visible gastric antrum on ultrasound
  • No known food allergies or sensitivities
  • Non restrained eaters (TFEQ, see below)
  • No history of gastrointestinal diseases that may interfere with eating behavior or digestion
  • Not on medications that affect appetite (including GLP-1 agonists), digestion, blood sugar regulation, saliva production, or chewing
  • Stable medication use
  • Non-smokers
  • Not gained or lost significant weight during the past 3 months
  • Regular monthly menstrual cycles
  • Not pregnant, lactating or

Exclusion criteria

Exclusion Criteria:

  • Diabetes or other metabolic disorders affecting glycemia and overall cardiometabolic health
  • Blood pressure > 140/90 mm Hg
  • Any food allergies, intolerances, or sensitivities
  • Pregnant or breastfeeding
  • Participation in another clinical trial
  • Excessive alcohol consumption (more than 14 drinks per week)
  • Smokers or those with a smoking history of more than 10 years
  • Regular use of recreational drugs (e.g., marijuana, ecstasy, LSD, magic mushrooms, etc.)
  • Restrained eater (>16) as defined by the questionnaire at screening (Three-Factor Eating Questionnaire, Stunkard et al., 1985)
  • Unusual sleep patterns
  • Irregular breakfast consumption
  • Recent weight changes, or intended weight loss or gain; lost/gained 10% of body weight within the last 6 months
  • Food allergies/sensitivities or any life-threatening allergies
  • Using medications known to affect appetite, digestion, blood sugar regulation, or chewing/swallowing (excluding oral ).
  • Experiences dry mouth in general or due to medication side effects
  • Inability to adhere to study protocols
  • Not comfortable providing IV-line blood samples
  • Not comfortable providing ultrasound scans
  • Not comfortable being video recorded while eating
  • Avoids consuming almonds/yogurt in general
  • Avoids eating hard foods to prevent dental fractures
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Whole - Chopped - Buttered

    Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, chopped almonds at the second intervention visit, and almonds processed into almond butter at the third intervention visit.

    Other: Yogurt with almonds

  • Experimental
    Whole - Buttered - Chopped

    Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, buttered almonds at the second intervention visit, and chopped almonds at the third intervention visit.

    Other: Yogurt with almonds

  • Experimental
    Buttered - Whole - Chopped

    Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, whole almonds at the second intervention visit, and chopped almonds at the third intervention visit.

    Other: Yogurt with almonds

  • Experimental
    Buttered - Chopped - Whole

    Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, chopped almonds at the second intervention visit, and whole almonds at the third intervention visit.

    Other: Yogurt with almonds

  • Experimental
    Chopped - Buttered - Whole

    Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, buttered almonds at the second intervention visit, and whole almonds at the third intervention visit.

    Other: Yogurt with almonds

  • Experimental
    Chopped - Whole - Buttered

    Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, whole almonds at the second intervention visit, and buttered almonds at the third intervention visit.

    Other: Yogurt with almonds

Interventions

  • OtherYogurt with almonds

    Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

06

What researchers measure

Primary outcomes

  1. Gastric emptying half-time

    Calculated from ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after consumption of the breakfast meal, in minutes

    Time frame: At each study visit, based on assessments at 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Secondary outcomes

  1. Eating time

    The time to consume the breakfast meal based on video recordings, in minutes

    Time frame: From 0 minutes until the end of eating the breakfast meal

  2. Changes from baseline in postprandial satiety visual analogue scale ratings

    Paper questionnaire scale ratings (in mm) of Hunger, Fullness, Prospective Consumption, and Desire to Eat where each is 100 mm ranging from 0 (minimum) to 100 (maximum). For example, 0 = Not at all Hungry and 100 = As Hungry as Possible.

    Time frame: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

  3. Changes from baseline in plasma triacylglycerol concentration

    Based on analysis of serial blood draws, in mmol/L

    Time frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

  4. Triacylglycerol response - incremental area under the curve (AUC)

    Calculated based on baseline and postprandial plasma concentrations

    Time frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

  5. Changes from baseline in plasma GLP-1 concentration

    Based on analysis of serial blood draws, in pg/mL

    Time frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

  6. GLP-1 response - incremental area under the curve (AUC)

    Calculated based on baseline and postprandial plasma concentrations

    Time frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

  7. Changes from baseline in plasma CCK concentration

    Based on analysis of serial blood draws, in pmol/L

    Time frame: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

  8. CCK response - incremental area under the curve (AUC)

    Calculated based on baseline and postprandial plasma concentrations

    Time frame: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

  9. Changes from baseline in gastric volume

    Calculated based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal, in mL

    Time frame: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

  10. Gastric volume - incremental area under the curve (AUC)

    Based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal

    Time frame: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Other outcomes

  1. Borg rating of perceived exertion

    Participant paper scale rating of effort required to chew the breakfast meal where 0 = No effort at all and 10 = Very very severe chewing effort

    Time frame: Immediately after the breakfast meal is consumed

  2. Changes from baseline in plasma blood glucose concentration

    Based on analysis of serial blood draws, in mmol/mL

    Time frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

  3. Glucose response - incremental area under the curve (AUC)

    Calculated based on baseline and postprandial plasma concentrations

    Time frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

  4. Changes from baseline in plasma blood insulin concentration

    Based on analysis of serial blood draws, in pmol/mL

    Time frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

  5. Insulin response - Area under the curve (AUC)

    Calculated based on baseline and postprandial plasma concentrations

    Time frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

  6. Product liking and perceived attributes

    Participant paper scale questionnaire ratings

    Time frame: Immediately after eating the breakfast meal

  7. Eating rate

    Calculated from video recordings of eating session, combining meal portion consumed (in grams) and eating time (minutes), grams/minute

    Time frame: From 0 minutes until the end of eating the breakfast meal

  8. Number of chews

    Determined by count from video recordings of each eating session

    Time frame: From 0 minutes until the end of eating the breakfast meal

07

Study locations

1 site
  • Department of Human Health Sciences
    Guelph, Ontario N1G 2G4, Canada
    • Amanda J Wright, PhD · Contactajwright@uoguelph.ca · 5190824-4120
    • Alison M Duncan, PhD · Contact
    • Amanda J Wright, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — Although we are not required to make this data available, we are currently working to understand how to do this in a safe way, as per our institutional guidelines. As we learn more, we may pursue this. We are obtaining consent from study participants for this option.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 18, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Dec 15, 2027
CompletionEst.
Dec 19, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944352
Lead sponsor
University of Guelph
Responsible party
Amanda Wright, Ph.D. (Professor, University of Guelph) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Dec 15, 2027 (estimated)
Completion
Dec 19, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Amanda J Wright, PhD
Contact
ajwright@uoguelph.ca
519-824-4120 ext. 54697

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion